Our story
Celltrion USA exists to help medicine keep pace with real life. As the North American affiliate of Celltrion, Inc.—a global biopharmaceutical innovator with more than 20 years of experience—we’re focused on building new possibilities in biologic care: greater access, more choices, and higher standards for patients and providers.
Founded in 2002, Celltrion has redefined access to high-quality therapies, launching the world’s first monoclonal antibody biosimilar and now reaching patients in 110+ countries. With US headquarters in New Jersey, we combine global research and development, deep manufacturing expertise, and regulatory excellence to build more possibilities for US patients.
Our collective global impact
3,153 EMPLOYEES GLOBALLY
20+
YEARS OF
MANUFACTURING
EXCELLENCE
12
MEDICINES
APPROVED GLOBALLY
32%
OF STAFF FOCUSED
ON R&D
10+
TREATMENTS IN
CLINICAL STAGES
12
MANUFACTURING
SITES WORLDWIDE
46+
SUBSIDIARIES
WORLDWIDE
952K+
PATIENTS REACHED
IN A SINGLE YEAR
FULLY INTEGRATED BIOPHARMACEUTICAL LEADER
316,000L
TOTAL PRODUCTION
CAPACITY
>$300M
INVESTMENT
IN R&D TO DATE
99%
MANUFACTURING
SUCCESS RATE
Meet our leadership
Jungjin Seo
Chairman/Founder, Celltrion Inc
Joonserk Seo
Chair of Board, Celltrion USA
BonJoong Kim
CEO, Celltrion USA
From our founder
Upon founding Celltrion in 2002, my vision was simple yet ambitious: to challenge convention and create a company that could improve lives by leading the way in biopharmaceutical innovation. With just $40,000 in capital, we took our first steps toward an idea that Korea could guide the world in biosimilar development. And this idea has since become reality.
Celltrion’s history is one of continuous innovation and perseverance. From developing Remsima, the world’s first monoclonal antibody biosimilar, to launching multiple breakthrough biopharmaceuticals, we have proven vision and determination can overcome even the humblest beginnings. With a well-established global presence, Celltrion continues its vision to transform global healthcare through novel drug development and providing the best care for all, creating new possibilities for patients and future generations.
I have always believed in the importance of onsite leadership. It is critical to meet partners face-to-face, listen directly to patients and healthcare professionals, and be on the ground to expand our global presence. That onsite leadership remains part of who we are today: a company driven by action and integrity.
In 2021, I was honored to be the first Korean entrepreneur to receive the EY World Entrepreneur of the Year award. Yet this recognition belongs not to me alone, but to everyone who believes in our vision.
As we move forward, my promise remains the same: to continue leading with purpose, pushing boundaries, and creating a future where advanced medicines are accessible to all.
Jungjin Seo
Founder & Chairman, Celltrion